Ascendis Pharma and Novo Nordisk Join Forces
Ascendis Pharma (ASND) has released an update. Ascendis Pharma has entered a collaboration with Novo Nordisk to license its ...
Ascendis Pharma’s Strategic Partnership with Novo Nordisk: A Promising Buy Opportunity Fueled by TransCon Technology
Wells Fargo analyst Derek Archila maintained a Buy rating on Ascendis Pharma (ASND – Research Report) yesterday and set a price target of ...
Ascendis Pharma’s Strategic Partnership with Novo Nordisk Signals Strong Buy Rating Amid Growing Obesity Market
In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ascendis Pharma (ASND – Research ...
Outsourcing-pharma1d
Novo Nordisk signs $285 million deal for a once-monthly GLP-1 receptor agonist
Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.
Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform
Ascendis Pharma (ASND) announced that it has granted Novo Nordisk (NVO) an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk ...
pharmaphorum3d
Novo puts $285m into monthly GLP-1 based on Ascendis tech
The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
Ascendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 ...
Pharmabiz2d
Ascendis Pharma, Novo Nordisk ink collaboration to develop & commercialize TransCon technology-based products in metabolic and cardiovascular diseases
Ascendis Pharma A/S announced that it has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary ...
Novo Nordisk, Ascendis partner to advance once-monthly obesity drug candidate
Novo Nordisk acquires exclusive worldwide license to Ascendis Pharma’s TransCon technology for developing metabolic and ...
Nasdaq4d
Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform
Ascendis Pharma (ASND) announced that it has granted Novo Nordisk (NVO) an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk ...